81 related articles for article (PubMed ID: 22580782)
1. Bully renal cysts knock down urine-concentrating capacity in the early rounds.
Grantham JJ
Clin J Am Soc Nephrol; 2012 Jun; 7(6):875-7. PubMed ID: 22580782
[No Abstract] [Full Text] [Related]
2. Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment.
Zittema D; Boertien WE; van Beek AP; Dullaart RP; Franssen CF; de Jong PE; Meijer E; Gansevoort RT
Clin J Am Soc Nephrol; 2012 Jun; 7(6):906-13. PubMed ID: 22516290
[TBL] [Abstract][Full Text] [Related]
3. Autosomal dominant polycystic kidney disease is associated with central and nephrogenic defects in osmoregulation.
Ho TA; Godefroid N; Gruzon D; Haymann JP; Maréchal C; Wang X; Serra A; Pirson Y; Devuyst O
Kidney Int; 2012 Nov; 82(10):1121-9. PubMed ID: 22718190
[TBL] [Abstract][Full Text] [Related]
4. Copeptin: a marker for ADPKD progression?
Fenske W; Wanner C
Nephrol Dial Transplant; 2012 Nov; 27(11):3985-7. PubMed ID: 22907952
[No Abstract] [Full Text] [Related]
5. Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease.
Boertien WE; Meijer E; Zittema D; van Dijk MA; Rabelink TJ; Breuning MH; Struck J; Bakker SJ; Peters DJ; de Jong PE; Gansevoort RT
Nephrol Dial Transplant; 2012 Nov; 27(11):4131-7. PubMed ID: 22523115
[TBL] [Abstract][Full Text] [Related]
6. Kidney function and plasma copeptin levels in healthy kidney donors and autosomal dominant polycystic kidney disease patients.
Zittema D; van den Berg E; Meijer E; Boertien WE; Muller Kobold AC; Franssen CF; de Jong PE; Bakker SJ; Navis G; Gansevoort RT
Clin J Am Soc Nephrol; 2014 Sep; 9(9):1553-62. PubMed ID: 24993447
[TBL] [Abstract][Full Text] [Related]
7. Association of Copeptin, a Surrogate Marker of Arginine Vasopressin, with Decreased Kidney Function in Sugarcane Workers in Guatemala.
Butler-Dawson J; Dally M; Johnson RJ; Johnson EC; Krisher L; Sánchez-Lozada LG; Griffin BR; Brindley S; Newman LS
Ann Nutr Metab; 2020; 76(1):30-36. PubMed ID: 32172243
[TBL] [Abstract][Full Text] [Related]
8. Urine and plasma osmolality in patients with autosomal dominant polycystic kidney disease: reliable indicators of vasopressin activity and disease prognosis?
Casteleijn NF; Zittema D; Bakker SJ; Boertien WE; Gaillard CA; Meijer E; Spithoven EM; Struck J; Gansevoort RT
Am J Nephrol; 2015; 41(3):248-56. PubMed ID: 25926129
[TBL] [Abstract][Full Text] [Related]
9. Urine Concentrating Capacity, Vasopressin and Copeptin in ADPKD and IgA Nephropathy Patients with Renal Impairment.
Zittema D; Casteleijn NF; Bakker SJ; Boesten LS; Duit AA; Franssen CF; Gaillard CA; Gansevoort RT
PLoS One; 2017; 12(1):e0169263. PubMed ID: 28081165
[TBL] [Abstract][Full Text] [Related]
10. Polycystic kidney disease: An early urea-selective urine-concentrating defect in ADPKD.
Bankir L; Bichet DG
Nat Rev Nephrol; 2012 Jun; 8(8):437-9. PubMed ID: 22735763
[No Abstract] [Full Text] [Related]
11. Renal concentrating capacity is linked to blood pressure in children with autosomal dominant polycystic kidney disease.
Seeman T; Dusek J; Vondrák K; Bláhová K; Simková E; Kreisinger J; Dvorák P; Kyncl M; Hríbal Z; Janda J
Physiol Res; 2004; 53(6):629-34. PubMed ID: 15588131
[TBL] [Abstract][Full Text] [Related]
12. Apelin and copeptin: two opposite biomarkers associated with kidney function decline and cyst growth in autosomal dominant polycystic kidney disease.
Lacquaniti A; Chirico V; Lupica R; Buemi A; Loddo S; Caccamo C; Salis P; Bertani T; Buemi M
Peptides; 2013 Nov; 49():1-8. PubMed ID: 23973863
[TBL] [Abstract][Full Text] [Related]
13. [Autosomal dominant (adult type) polycystic kidney disease].
Higashihara E; Nutahara K
Nihon Hinyokika Gakkai Zasshi; 1991 Oct; 82(10):1545-60. PubMed ID: 1722832
[No Abstract] [Full Text] [Related]
14. An abnormal apelin/vasopressin balance may contribute to water retention in patients with the syndrome of inappropriate antidiuretic hormone (SIADH) and heart failure.
Blanchard A; Steichen O; De Mota N; Curis E; Gauci C; Frank M; Wuerzner G; Kamenicky P; Passeron A; Azizi M; Llorens-Cortes C
J Clin Endocrinol Metab; 2013 May; 98(5):2084-9. PubMed ID: 23515451
[TBL] [Abstract][Full Text] [Related]
15. [Renal manifestation of Autosomal Dominant Polycystic Kidney Disease].
Galliani M; Chicca S; Vitaliano E; Di Lullo L; Giannakakis K; Paone A
G Ital Nefrol; 2018 Mar; 35(2):. PubMed ID: 29582957
[TBL] [Abstract][Full Text] [Related]
16. Prohormones: novel biomarkers for corticosteroids in septic shock?
Annane D
Intensive Care Med; 2008 Mar; 34(3):395-6. PubMed ID: 18080110
[No Abstract] [Full Text] [Related]
17. Normal fractional urate excretion identifies hyponatremic patients with reset osmostat.
Imbriano LJ; Ilamathi E; Ali NM; Miyawaki N; Maesaka JK
J Nephrol; 2012; 25(5):833-8. PubMed ID: 22307440
[TBL] [Abstract][Full Text] [Related]
18. Sexual disparity of copeptin in healthy newborn infants.
Burckhardt MA; Wellmann M; Fouzas S; Lapaire O; Burkhardt T; Benzing J; Bührer C; Szinnai G; Wellmann S
J Clin Endocrinol Metab; 2014 Sep; 99(9):E1750-3. PubMed ID: 25004250
[TBL] [Abstract][Full Text] [Related]
19. Clinical analysis of hyponatremia in acute craniocerebral injury.
Zhang W; Li S; Visocchi M; Wang X; Jiang J
J Emerg Med; 2010 Aug; 39(2):151-7. PubMed ID: 18722740
[TBL] [Abstract][Full Text] [Related]
20. Cystatin C estimated glomerular filtration rate to assess renal function in early stages of autosomal dominant polycystic kidney disease.
Sans L; Radosevic A; Quintian C; Montañés R; Gràcia S; Vilaplana C; Mojal S; Ballarin JA; Fernández-Llama P; Torra R; Pascual J
PLoS One; 2017; 12(3):e0174583. PubMed ID: 28346513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
